Cholesterol induces resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) via the EGFR/Src/Erk/SP1 signaling pathway 31, while elevated levels in lipid rafts induce gefitinib resistance 109. Here, SP1 is linked to non-small cell lung carcinoma.